A team published a hybrid capture–based targeted NGS approach that amplifies detection of circulating microbial cell‑free DNA in blood plasma, enabling broader pathogen discovery and potential improvements in sepsis and infectious‑disease diagnostics. The method expands coverage across bacterial, viral and fungal genomes in a single assay. Authors demonstrated enhanced sensitivity and a capacity to identify unexpected or low‑abundance pathogens directly from plasma samples, which could shorten diagnostic delays and guide targeted therapy. The approach leverages deep sequencing and broad probe design to capture diverse microbial cfDNA. Translational steps include prospective clinical validation, workflow integration in hospital labs, and cost‑effectiveness analysis prior to routine adoption in acute care settings.